down arrow

Genprex, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3724462037
USD
3.35
0.61 (22.26%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.083.68

52 Week

2.6163.00
Valuation
Technical
Day's Volume

CASH

1.86 M

Shareholding (Mar 2025)

FII

0.54%

Held by 7 FIIs

DII

97.92%

Held by 2 DIIs

Promoter

0.00%

How big is Genprex, Inc.?

22-Jun-2025

As of Jun 18, Genprex, Inc. has a market capitalization of 8.70 million, with net sales of 0.00 million and a net profit of -19.11 million over the last four quarters. The company reported shareholder's funds of 1.62 million and total assets of 4.12 million as of Dec 24.

Market Cap: As of Jun 18, Genprex, Inc. has a market capitalization of 8.70 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Genprex, Inc. reported net sales of 0.00 million and a net profit of -19.11 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1.62 million and total assets of 4.12 million.

Read More

What does Genprex, Inc. do?

22-Jun-2025

Genprex, Inc. is a clinical-stage gene therapy company focused on developing cancer therapies, with a market cap of USD 8.70 million and recent net profits of -4 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.

Overview: <BR>Genprex, Inc. is a clinical-stage gene therapy company focused on developing cancer therapies and is categorized within the Pharmaceuticals & Biotechnology industry, with a market cap of USD 8.70 Million.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 8.70 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.90 <BR>Return on Equity: -493.99% <BR>Price to Book: 2.25<BR><BR>Contact Details: <BR>Address: 1601 Trinity St Bldg B, AUSTIN TX: 78712-1765 <BR>Tel: 1 512 5377997 <BR>Website: https://www.genprex.com/

Read More

Who are in the management team of Genprex, Inc.?

22-Jun-2025

As of March 2022, the management team of Genprex, Inc. includes J. Rodney Varner as Chairman, President, CEO, and Secretary, along with independent directors Brent Longnecker, Jose Moreno Toscano, and William Wilson.

As of March 2022, the management team of Genprex, Inc. includes Mr. J. Rodney Varner, who serves as the Chairman of the Board, President, Chief Executive Officer, and Secretary. Additionally, the board features independent directors: Mr. Brent Longnecker, Mr. Jose Moreno Toscano, and Mr. William Wilson.

Read More

Is Genprex, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Genprex, Inc. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 significantly, with a year-to-date return of -71.29% compared to the S&P's 12.22%.

As of 12 September 2025, the technical trend for Genprex, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI is bearish on the weekly and shows no signal on the monthly. Bollinger Bands indicate a bearish stance on both time frames, and moving averages are mildly bearish on the daily. KST is mildly bullish on both weekly and monthly, while the Dow Theory shows no trend weekly and bearish monthly. OBV is bullish monthly but shows no trend weekly. <BR><BR>In terms of performance, Genprex has underperformed the S&P 500 across multiple periods, with a year-to-date return of -71.29% compared to the S&P 500's 12.22%, and a one-year return of -33.01% versus 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.97

stock-summary
Return on Equity

-1,242.53%

stock-summary
Price to Book

4.95

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-59.17%
0%
-59.17%
6 Months
-76.62%
0%
-76.62%
1 Year
-93.85%
0%
-93.85%
2 Years
-99.29%
0%
-99.29%
3 Years
-99.87%
0%
-99.87%
4 Years
-99.87%
0%
-99.87%
5 Years
-99.95%
0%
-99.95%

Genprex, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Genprex, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Genprex, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI is bearish on the weekly and shows no signal on the monthly. Bollinger Bands indicate a bearish stance on both time frames, and moving averages are mildly bearish on the daily. KST is mildly bullish on both weekly and monthly, while the Dow Theory shows no trend weekly and bearish monthly. OBV is bullish monthly but shows no trend weekly. In terms of performance, Genprex has underperformed the S&P 500 across multiple periods, with a year-to-date return of -71.29% compared to the S&P 500's 12.22%, and a one-year return of -33.01% versus 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-3.72%
EBIT to Interest (avg)
-22.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.51%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.07
EV to EBIT
-0.24
EV to EBITDA
-0.24
EV to Capital Employed
4.53
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1914.67%
ROE (Latest)
-493.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (1.54%)

Foreign Institutions

Held by 7 Foreign Institutions (0.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 27.69% vs 18.75% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.70",
          "val2": "-6.50",
          "chgp": "27.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.70",
          "val2": "-6.50",
          "chgp": "27.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 31.72% vs -30.38% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.20",
          "val2": "-31.10",
          "chgp": "31.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.10",
          "val2": "-30.90",
          "chgp": "31.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.70
-6.50
27.69%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.70
-6.50
27.69%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 27.69% vs 18.75% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-21.20
-31.10
31.83%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-21.10
-30.90
31.72%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 31.72% vs -30.38% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Genprex, Inc. stock-summary
stock-summary
Genprex, Inc.
Pharmaceuticals & Biotechnology
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).
Company Coordinates stock-summary
Company Details
1601 Trinity St Bldg B , AUSTIN TX : 78712-1765
stock-summary
Tel: 1 512 5377997
stock-summary
https://www.genprex.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."